Newsletter | April 2024

Apply Now: 2025 Grants and Fellowships

Submit Your Letter of Intent by May 1 @ 12:00 p.m. (Noon) ET

Predoctoral Fellowships: $30,000 a year for up to two years

Postdoctoral Fellowships: $60,000 a year for up to two years

Faculty Starter Grants: $100,000 for one year

Application Advice From a Reviewer

A longtime member of the Foundation’s Drug Discovery Scientific Advisory Committee discusses what he looks for when reviewing applications in a recent webinar and blog. David Aldous, PhD, Head of Global R&D Processes and Operations at Sanofi, shares the types of research projects that excite him and what things — both good and bad — catch his attention in an application.

The PhRMA Foundation's Annual Report outlines our efforts to support early-career researchers and to address issues important to industry through research funding opportunities. Read the report to learn about the research projects of our 2023 award recipients.

Supporting New Faculty With Critical Research Funding

Christopher Cadham (PhF23) of the University of Michigan received a travel award to attend ISPOR 2024 in May, where he will present "Public Preferences for Improving Health Equity: A Qualitative Focus Group Study," which was funded by his PhRMA Foundation award.

Dr. Andy Daniel (PhF22) of the University of California, San Francisco, won the Novocure Award for the Best Cancer Neuroscience Overall Abstract at the 2024 Cancer Neuroscience Symposium at The University of Texas MD Anderson Cancer Center in February for his abstract "Electrophysiological and spatially resolved genomic signatures of glioma-infiltrated cortex."

Rhashanda Haywood (PhF23) of the University of Maryland, Eastern Shore, received a 2024 Merck Chemists of Color Research Award as well as a travel award to attend the American Society for Pharmacology and Experimental Therapeutics (ASPET) conference in May.

Dr. Vasco M Pontinha (PhF21) of Virginia Commonwealth University will present at two sessions during ISPOR 2024:

• "Health Equity Considerations in Economic Evaluations," Monday, May 5 @1:45 p.m.
• "How to Adjust Economic Models for Health Equity in the Conduct of Generalized Cost-Effectiveness Analysis (GCEA)," Wednesday, May 8 @ 10 a.m.

Dr. Srividya Swaminathan (PhF21) has been promoted to Associate Professor of Systems Biology at the Beckman Research Institute, City of Hope. "By being the first sponsor of my independent research, PhRMA Foundation provided me the platform to procure additional funding for my research and publish high impact papers ... all these ultimately culminating in my promotion," she said.

Congrats to these Foundation-funded researchers on their recent work.

**Indicates research directly supported by a PhRMA Foundation award.

**Modifying peptide/lipid-associated nucleic acids (PLANAs) for CRISPR/Cas9 ribonucleoprotein delivery, European Journal of Pharmaceutical Sciences

Hamidreza Montazeri, PharmD, PhD, Chapman University

Risk preferences over health: Empirical estimates and implications for medical decision-making, Journal of Health Economics

Karen Mulligan, PhD, University of Southern California (PhF23)

Racial and ethnic differences in disease course Medicare expenditures for beneficiaries with dementia, Journal of the American Geriatrics Society

Natalia Olchanski, PhD, Tufts Medical Center (PhF21)

Life-Sustaining Treatments Among Medicare Beneficiaries with and without Dementia at the End of Life, Journal of Alzheimer's Disease

Natalia Olchanski, PhD, Tufts Medical Center (PhF21)

Addressing Opioid Use Disorder in Primary Care: Revisiting Core Primary Care Principles to Confidently Initiate Treatment, Journal of General Internal Medicine

Jarratt Pytell, MD, University of Colorado (PhF23)

**Validating claims-based definitions for deprescribing: Bridging the gap between clinical and administrative data, Pharmacoepidemiology and Drug Safety

Shahar Shmuel, PhD, University of North Carolina at Chapel Hill (PhF20)

**Visualizing External Validity: Graphical Displays to Inform the Extension of Treatment Effects from Trials to Clinical Practice, Epidemiology

Shahar Shmuel, PhD, University of North Carolina at Chapel Hill (PhF20)

**Imidazolium-based zwitterionic liquid-modified PEG–PLGA nanoparticles as a potential intravenous drug delivery carrier, Nanoscale

Eden Tanner, PhD, University of Mississippi (PhF22)

Choline Carboxylic Acid Ionic Liquid-Stabilized Anisotropic Gold Nanoparticles for Photothermal Therapy, ACS Applied Nano Materials

Eden Tanner, PhD, University of Mississippi (PhF22)

Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force, PharmacoEconomics

Wendy J. Ungar, PhD, Hospital for Sick Children Research Institute (PhF20)

A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects, PharmacoEconomics

Wendy J. Ungar, PhD, Hospital for Sick Children Research Institute (PhF20)

Did someone forward this to you?

Subscribe to get updates and funding announcements directly in your inbox.

www.phrmafoundation.org